Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2018 - 2021)

Fulcrum Therapeutics (FULC) has 4 years of Non-Current Deffered Revenue data on file, last reported at $1.7 million in Q4 2021.

• On a quarterly basis, Non-Current Deffered Revenue rose 1.88% year-over-year to $1.7 million in Q4 2021; TTM through Dec 2021 was $1.7 million, a 1.88% increase from a year earlier, with the FY2021 full-year figure at $1.7 million, up 1.88% from the prior year.
• Non-Current Deffered Revenue for Q4 2021 stood at $1.7 million, up from $1.6 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for FULC reached as high as $6.0 million in Q4 2019 and fell as low as $1.4 million in Q4 2018.
• Historically, Non-Current Deffered Revenue has averaged $2.4 million across 4 years, with a median of $1.6 million in 2020.
• Across the five-year window, Non-Current Deffered Revenue soared 328.74% in 2019 and tumbled 72.57% in 2020, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.4 million in 2018, then surged by 328.74% to $6.0 million in 2019, then tumbled by 72.57% to $1.6 million in 2020, then advanced by 1.88% to $1.7 million in 2021.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.7 million in Q4 2021, $1.6 million in Q3 2021, and $1.7 million in Q2 2021.